Sanofi, Enjaymo and Recordati
YAHOO!Finance · 9h
Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo For $825M Upfront To Italian Firm Recordati
Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ:SNY) for $825 million as an upfront payment and additional commercial milestone payments of up to $250 million.
FiercePharma · 10h
In sustained rare disease push, Recordati lays out $825M upfront to acquire Sanofi's CAD drug Enjaymo
As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating $825 million upfront—plus another $250 million in potential commercial milestones—to get its hands on the global rights to Sanofi’s rare disease biologic Enjaymo.
BioSpace · 11h
Sanofi Offloads Rare Autoimmune Drug to Recordati in Potential $1B Deal
Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights to a biologic for the treatment of cold agglutinin disease, with milestone payments of up to $250 million.
ENDPOINTS NEWS · 13h
Sanofi sells rare disease drug Enjaymo to Recordati for $825M upfront
Sanofi is offloading its rare autoimmune disease medicine Enjaymo to an Italian pharmaceutical company for $825 million upfront. Recordati, based in Milan, said Friday it will pay up to an additional $250 million over time for the monoclonal antibody,
Benzinga.com · 9h
Sanofi Sells Global Rights To Rare Autoimmume Drug Enjaymo For $825M Upfront To Italian Firm Recordati
Recordati will acquire global rights to Enjaymo from Sanofi for $825M, boosting its rare disease portfolio. The deal includes milestone payments and is expected to close by the end of 2024.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results